Squamous cell carcinoma - Skvamoĉela Karcinomo
☆ En la 2022 Stiftung Warentest rezultoj de Germanio, konsumanto kontento kun ModelDerm estis nur iomete pli malalta ol kun pagitaj telemedicinaj konsultoj.
Squamous cell carcinoma well differentiated ― Oni observas apudan aktina keratozo.
References
Squamous cell carcinoma (SCC) estas la dua plej ofta haŭta kancero en Usono, post basal cell carcinoma. Ĝi kutime komenciĝas de antaŭkanceraj lezoj nomitaj actinic keratosis , kaj povas disvastiĝi al aliaj partoj de la korpo. La ĉefa kaŭzo estas eksponiĝo al ultraviola (UV) radiado de la suno, kiu akumuliĝas kun la tempo. Terapio kutime implikas kirurgian forigon, precipe por SCC sur la kapo kaj kolo. Radioterapio estas elekto por pli maljunaj pacientoj aŭ tiuj kiuj ne povas havi kirurgion. Imunsubpremo pliigas la riskon de SCC. Kvankam malofta, SCC povas disvastiĝi, precipe en pacientoj kun malfortigitaj imunsistemoj. Regulaj kontroloj kaj sunprotekto estas gravaj por tiuj kun SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) estas la dua plej ofta kancero en homoj, kaj ĝiaj nombroj pliiĝas. Kvankam CSCC kutime montras benignan klinikan konduton, ĝi povas disvastiĝi kaj loke kaj al aliaj partoj de la korpo. Sciencistoj identigis specifajn vojojn implikitajn en CSCC-evoluo, kondukante al novaj traktadoj. La alta nombro da mutacioj kaj pliigita risko en imunodeprimitaj pacientoj instigis la evoluon de imunoterapio. Ĉi tiu revizio rigardas la genetikajn radikojn de CSCC kaj la plej novajn traktadojn celantajn specifajn molekulojn kaj la imunsistemon.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnozo kaj Traktado
#Dermoscopy
#Skin biopsy